Alnylam presents cardiovascular data at ACC conference

Alnylam reported revenue of $3.71B (up 65% YoY), diluted EPS of $2.33 and a gross margin of 81.64%, with InvestingPro forecasting EPS of $9.65 for FY2026. HELIOS-B analyses showed vutrisiran improved quality-of-life and, among patients progressing to advanced disease, reduced all-cause mortality and recurrent cardiovascular events by 40% overall and 46% in the monotherapy population; real-world adherence was 93.8% over a mean 613.8 days. Pooled Phase 2 safety data for zilebesiran were favorable and the Phase 3 ZENITH outcomes trial (co-developed with Roche) launched in Sept 2025. Multiple firms reiterated ratings with price targets of $510 (H.C. Wainwright), $444 (Stifel), $460 (BofA) and $360 (Morgan Stanley equalweight), while InvestingPro notes the stock trades slightly above a $298.39 fair value — likely to move the stock but not market-wide.

Analysis

The commercial and diagnostic ecosystem is the proximate alpha: AI-enabled screening and care-coordination partnerships are likely to expand diagnosed ATTR-CM incidence materially over the next 24–36 months, which magnifies near-term revenue growth but also accelerates competitive attention and payer scrutiny. Co-development with a large pharma partner de-risks late‑stage investment and distribution logistics, but it also means margin sharing and potential sequencing of launches that can compress long‑term gross margins versus a solo commercialization path.

Manufacturing and supply-chain capacity for subcutaneous RNA therapeutics is a non-obvious choke point — if uptake scales faster than contract manufacturing ramp, incremental product margin could fall 300–700 bps in the first 12 months of peak demand absent forward-contracted capacity. Conversely, stable high adherence observed in early cohorts should increase lifetime patient value by shortening time-to-revenue per patient, but sustaining that adherence across broader, less-selected populations is an open 12–24 month experiment.

The biggest near-term catalyst mix is reimbursement and label differentiation: positive outcomes in high-risk subgroups will help secure favorable coverage but also invite price compression if multiple therapies reach market within 18–36 months. Tail risks include an adverse safety signal in wider population use, aggressive payer cost-effectiveness thresholds forcing outcomes‑based contracts, or a surprise oral competitor that materially lowers administration cost and thus market share over 2–4 years.

Key Decisions for Investors

• Directional long ALNY (50–100bp portfolio exposure) — accumulate on pullbacks of 8–15% into 3–9 month windows tied to commercial uptake datapoints; hedge with 6–9 month 25–30% OTM puts sized at 25% of the notional to cap downside (expected R/R: target +30–50% upside vs protected -8–12% downside).
• Options spread to express asymmetric upside: buy 12–18 month ALNY call LEAP and sell a nearer in strike call (debit call spread) to lower cost. Trade if you believe commercialization beats: aim for 2:1 upside/downside skew (pay no more than 60% of max upside premium).
• Event pair trade (12–24 months): long ALNY equity / short a broader small-cap RNA-biotech index or ETF to isolate company-specific commercialization upside while neutralizing sector regulatory risk. Size net delta to ~30–50bp long to capture idiosyncratic outperformance.
• Tactical risk-off: if payer contract negotiations headline negatively, exit or cut exposure quickly — set stop-loss at 12% absolute drawdown from average entry or trigger on a single negative CMS/major-insurer coverage decision. Expected payoff: preserves capital for redeployment into other accelerated-adoption winners.
• Monitor manufacturing signals — if management announces forward capacity deals or CMO expansions, add to position (buy on announcement within 48 hours). If there are supply delays or dose shortages, trim to half exposure and buy short-dated puts to hedge until supply visibility clears.